Connection
Gregory Schwartz to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications Gregory Schwartz has written about Clinical Trials, Phase II as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.040 |
|
|
|
-
Haarhaus M, Ray KK, Nicholls SJ, Schwartz GG, Kulikowski E, Johansson JO, Sweeney M, Halliday C, Lebioda K, Wong N, Brandenburg V, Beddhu S, Tonelli M, Zoccali C, Kalantar-Zadeh K. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 2019 11; 290:59-65.
Score: 0.040